The European Union, France, and Nigeria have signed a €10.2 million agreement to strengthen Nigeria’s pharmaceutical manufacturing capacity and boost local medicine production. Announced on November 2, 2025, in Abuja, the partnership, part of the EU’s Global Gateway “Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+)” initiative, is designed to enhance the country’s self-sufficiency in essential drugs, improve healthcare delivery, and stimulate industrial growth through research, innovation, and job creation.
The project, known as Quality Uplift for Advancing Local Industry in Medicine Standards (QUALIMED), will be implemented in collaboration with Nigeria’s National Institute for Pharmaceutical Research and Development (NIPRD), which is being upgraded into a regional reference centre for medicine quality control, bio-equivalence testing, and stability studies. By supporting the institute, the partnership aims to further reduce Nigeria’s reliance on imported medicines and ensure that locally produced drugs meet international quality standards.
Funded jointly by the EU, France, and Nigeria, the initiative aligns with broader efforts to localize medicine production across Africa. It will foster technology transfer, strengthen regulatory systems, and train local scientists and pharmaceutical workers. The project will also promote gender inclusion in biomanufacturing and connect Nigeria’s pharmaceutical sector with global supply chains and innovation networks.
Beyond healthcare, the agreement is expected to create skilled jobs, attract investment, and position Nigeria as a regional hub for high-quality pharmaceutical manufacturing. It also aligns with Nigeria’s goal of achieving medicine security while driving industrial diversification. If effectively implemented, QUALIMED could transform Nigeria’s pharmaceutical landscape, reduce the cost of medicines, and make the country a major player in West Africa’s health economy.
No comments:
Post a Comment